Cargando…

NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM

BACKGROUND: Plexiform neurofibromas (PNs) can cause significant morbidity. In this phase 2 study, we assessed imaging and functional outcomes to the MEK-inhibitor Binimetinib in pediatric patients with PNs. METHODS: Children (age 1–17 years) with PN that were progressive or causing significant morbi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mueller, Sabine, Reddy, Alyssa T, Dombi, Eva, Allen, Jeffrey, Packer, Roger, Clapp, Wade, Goldman, Stewart, Schorry, Elizabeth, Tonsgard, James, Blakeley, Jaishri, Ullrich, Nicole J, Gross, Andrea, Walsh, Karin, Thomas, Coretta, Edwards, Lloyd, Prados, Michael, Korf, Bruce, Fisher, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neurofibromatosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715338/ http://dx.doi.org/10.1093/neuonc/noaa222.619

Ejemplares similares

NFB-14. PSYCHOSOCIAL OUTCOMES IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS
por: Damodharan, Sudarshawn, et al.
Publicado: (2020)

NFB-13. TRAMETINIB FOR PLEXIFORM NEUROFIBROMA AND RECURRENT LOW-GRADE GLIOMA
por: Sato, Aimee, et al.
Publicado: (2020)

NFB-03. TRAMETINIB FOR ORBITAL PLEXIFORM NEUROFIBROMAS IN YOUNG CHILDREN WITH NF1
por: Toledano, Helen, et al.
Publicado: (2020)

NFB-12. TRAMETINIB THERAPY FOR PEDIATRIC PATIENTS WITH REFRACTORY LOW GRADE GLIOMA OR EXTENSIVE SYMPTOMATIC PLEXIFORM NEUROFIBROMA
por: Hounjet, Celine D, et al.
Publicado: (2020)

NFB-07. USE OF PEGYLATED INTERFERON α- 2b IN PEDIATRIC PATIENTS AFFECTED BY UNRESECTABLE PLEXIFORM NEUROFIBROMAS: MONOCENTRIC EXPERIENCE
por: Cacchione, Antonella, et al.
Publicado: (2020)

NFB-08. TRAM-01: A Phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
por: Kiaei, Dorsa Sadat, et al.
Publicado: (2022)

NFB-08. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
por: Phadnis, Sheetal, et al.
Publicado: (2020)

NFB-05. AN UNUSUAL PRESENTATION OF RECURRENT LANGERHANS CELL HISTIOCYTOSIS OF THE CRANIOFACIAL BONES IN A PATIENT WITH NEUROFIBROMATOSIS TYPE I
por: Chaffee, Blake, et al.
Publicado: (2020)

NFB-18. IMMUNE FUNCTION IN CHILDREN TREATED WITH TRAMETINIB
por: Moukhaiber, Perla, et al.
Publicado: (2020)

NFB-12. Effect of trametinib on leg length discrepancy in a child with NF1 related plexiform neurofibroma
por: Pradeep, Celia, et al.
Publicado: (2022)

NFB-02. TREATMENT OF PAIN AND TUMOR GROWTH IN NF2
por: Hemenway, Molly, et al.
Publicado: (2020)

NFB-04. EXAMINING DIFFUSION, ARTERIAL SPIN-LABELED PERFUSION, AND VOLUMETRIC CHANGES IN THE NEUROFIBROMATOSIS TYPE 1 BRAIN USING AN ATLAS-BASED, MULTI-PARAMETRIC APPROACH
por: Tam, Lydia, et al.
Publicado: (2020)

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
por: Weiss, Brian D., et al.
Publicado: (2021)

NFB-11. WHITE MATTER DIFFERENCES IN CHILDREN WITH NF1 COMPARED TO CONTROLS
por: Bruckert, Lisa, et al.
Publicado: (2020)

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY
por: Fisher, Michael J, et al.
Publicado: (2020)

NFB-01. FUNCTIONAL CHARACTERIZATION OF ATRX LOSS IN NF1-ASSOCIATED GLIOMA AND MPNST
por: Yuan, Ming, et al.
Publicado: (2020)

NFB-15. "Cognitive Impairments in Children and Adolescents with Neurofibromatosis"
por: Mavrea, Kalliopi, et al.
Publicado: (2022)

NFB-16. mTOROPATHIES AND SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: PREDICTIVE VALUE OF GERMINAL TSC1/2 MUTATIONS SCREENING IN FAMILIAL CASES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2020)

NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
por: Baig, Muhammed, et al.
Publicado: (2020)

NFB-21. Neurofibromatosis Type I in the Setting of Neuro-Oncology
por: Hemenway, Molly
Publicado: (2022)

NFB-17. "Optic Pathway findings in children with Neurofibromatosis type-1 (NF-1)
por: Roka, Kleoniki, et al.
Publicado: (2022)

NFB-03. Neurological manifestations in children and adolescents with Neurofibromatosis type 1 - Implications for management and surveillance
por: Angelova-Toshkina, Daniela, et al.
Publicado: (2022)

A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1
por: Heaney, Alice, et al.
Publicado: (2019)

NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B
por: Pillay Smiley, Natasha, et al.
Publicado: (2022)

Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells
por: Ferrer, Marc, et al.
Publicado: (2018)

NFB-07. Meningiomatosis in an adolescent with TRAF-7 mutation related syndrome
por: Torres, Marleni, et al.
Publicado: (2022)

NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas
por: Putnam, Ethan, et al.
Publicado: (2022)

The development of the PlexiQoL: A patient‐reported outcome measure for adults with neurofibromatosis type 1‐associated plexiform neurofibromas
por: Heaney, Alice, et al.
Publicado: (2020)

Plexiform Neurofibroma in the Axilla with Intraosseous Neurofibroma in the Humerus in Neurofibromatosis 5
por: Khaladkar, Sanjay Mhalasakant, et al.
Publicado: (2018)

NFB-05. A family-centered neurocutaneous syndrome clinic in the age of targeted therapies
por: Marks, Asher, et al.
Publicado: (2022)

NFB-09. Treatment of cardiac fibroma in aPTCH1-mutated Gorlin syndrome with medulloblastoma
por: Piccolo, Gianluca, et al.
Publicado: (2022)

NFB-06. Laser Interstitial Thermal Therapy as a Radiation-Sparing Approach for Children with Cancer Predisposition
por: Guadix, Sergio, et al.
Publicado: (2022)

Congenital Craniofacial Plexiform Neurofibroma in Neurofibromatosis Type 1
por: Cacchione, Antonella, et al.
Publicado: (2021)

Giant Pelvic Neurofibroma in Patient with Plexiform Sciatic Neurofibroma and Neurofibromatosis Type 1
por: Temelkova, Ivanka, et al.
Publicado: (2019)

Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1
por: Nguyen, Rosa, et al.
Publicado: (2012)

Resection of small plexiform neurofibromas in neurofibromatosis type 1 children
por: Friedrich, Reinhard E, et al.
Publicado: (2005)

NFB-23. Extent of tumor but not location may be predictive of longitudinal disease severity in children with NF1-associated gliomas requiring treatment
por: Chaturvedi, Sneha, et al.
Publicado: (2022)

NFB-02. Maternal high-fat diet exposure increases the proliferation and glial differentiation of the cells of origin for NF1-optic glioma
por: Zhang, Kailong, et al.
Publicado: (2022)

Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas
por: Armstrong, Amy E., et al.
Publicado: (2023)

MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK
por: Na, Youjin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p4ehpplmdkh37puvt8b9pdk5dr